APM
KURA icon

Avidity Partners Management’s Kura Oncology KURA Stock Holding History

Avidity Partners Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-347,645
Closed -$11.4M – 110
2020
Q4 		$11.4M Buy
+347,645
New +$12.2M 0.37% 64

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Avidity Partners Management's KURA Position: Q1 2021 in Review

Avidity Partners Management sold out of Kura Oncology (KURA) in Q1 2021, closing a stake of 347,645 shares — an estimated $11.4M sold.

Avidity Partners Management first reported a position in KURA in Q4 2020 and held it in 1 quarter. The position peaked at $11.4M in Q4 2020. 171 funds tracked by Wall St. Rank hold KURA as of Q1 2021.

  • Avidity Partners Management reported no remaining Kura Oncology position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 347,645 Kura Oncology shares in Q1 2021, an estimated $11.4M.
  • Avidity Partners Management first reported a position in Kura Oncology in Q4 2020 and held it in 1 quarter.
  • Avidity Partners Management's Kura Oncology position peaked at $11.4M in Q4 2020.
  • 171 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.